Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects

American Journal of Physiology - Endocrinology and Metabolism

Volumn 284, Issue 1 47-1, 2003, Pages

  Qvigstad, Elisabeth ^a   Mostad, Ingrid L ^a   Bjerve, Kristian S ^a   Grill, Valdemar E ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Acipimox; Hypertriglyceridemia; Insulin sensitivity; Lipotoxicity; Low fat diet

Indexed keywords

ACIPIMOX; FATTY ACID; HEPARIN; INSULIN; INTRALIPID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET THERAPY; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; LOW FAT DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0037225537     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00114.2002     Document Type: Article

References (42)

1. Andersen LF, Solvoll K, and Drevon CA. Very-long-chain n-3 fatty acids as biomarkers for intake of fish and n-3 fatty acid concentrates. Am J Clin Nutr 64: 305-311, 1996.
2. Anonymous. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285: 2486-2497, 2001.
3. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46: 3-10, 1997.
4. Boden G, Chen X, Rosner J, and Barton M. Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 44: 1239-1242, 1995.
5. Bonaa KH, Bjerve KS, Straume B, Gram IT, and Thelle D. Effect of eicosapentaenoic and docosahexaenoic acids on blood pressure in hypertension. A population-based intervention trial from the Tromso study. N Engl J Med 322: 795-801, 1990.
6. Carpentier A, Mittelman SD, Bergman RN, Giacca A, and Lewis GF. Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. Diabetes 49: 399-408, 2000.
7. Carpentier A, Mittelman SD, Lamarche B, Bergman RN, Giacca A, and Lewis GF. Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. Am J Physiol Endocrinol Metab 276: E1055-E1066, 1999.
8. Charles MA, Eschwege E, Thibult N, Claude JR, Warnet JM, Rosselin GE, Girard J, and Balkau B. The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: Results of the Paris Prospective Study. Diabetologia 40: 1101-1106, 1997.
9. Claudi T, Midthjell K, Holmen J, Fougner K, Kruger O, and Wiseth R. Cardiovascular disease and risk factors in persons with type 2 diabetes diagnosed in a large population screening: The Nord-Trondelag Diabetes Study, Norway. J Intern Med 248: 492-500, 2000.
10. Close EJ, Wiles PG, Lockton JA, Walmsley D, Oldham J, and Wales JK. Diabetic diets and nutritional recommendations: What happens in real life? Diabet Med 9: 181-188, 1992.
11. DeFronzo RA, Tobin JD, and Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab Gastrointest Physiol 237: E214-E223, 1979.
12. Glauber H, Wallace P, Griver K, and Brechtel G. Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern Med 108: 663-668, 1988.
13. Haffner SM, D'Agostino R Jr, Mykkanen L, Tracy R, Howard B, Rewers M, Selby J, Savage PJ, and Saad MF. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: The Insulin Resistance Atherosclerosis Study. Diabetes Care 22: 562-568, 1999.
14. Hill JO, Peters JC, Reed GW, Schlundt DG, Sharp T, and Greene HL. Nutrient balance in humans: Effects of diet composition. Am J Clin Nutr 54: 10-17, 1991.
15. Hovorka R, Soons PA, and Young MA. ISEC: A program to calculate insulin secretion. Comput Methods Programs Biomed 50: 253-264, 1996.
16. Hu FB, van Dam RM, and Liu S. Diet and risk of type II diabetes: The role of types of fat and carbohydrate. Diabetologia 44: 805-817, 2001.
17. Kelley DE and Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: A reexamination. Diabetes 49: 677-683, 2000.
18. Matzkies F, Webs B, Rusche R, and Dirks K. [Nutritional behavior of non-insulin-dependent type II diabetes patients using the KALI 2.12 computer program]. Z Ernahrungswiss 26: 84-99, 1987.
19. McGarry JD and Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 42: 128-138, 1999.
20. Nes M, Frost AL, Solvoll K, Sandstad B, Hustvedt BE, Lovo A, and Drevon CA. Accuracy of a quantitative food frequency questionnaire applied in elderly Norwegian women. Eur J Clin Nutr 46: 809-821, 1992.
21. Ostenson CG. The pathophysiology of type 2 diabetes mellitus: An overview. Acta Physiol Scand 171: 241-247, 2001.
22. Paolisso G, Gambardella A, Amato L, Tortoriello R, D'Amore A, Varricchio M, and D'Onofrio F. Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia 38: 1295-1299, 1995.
23. Paolisso G, Tagliamonte MR, Rizzo MR, Gualdiero P, Saccomanno F, Gambardella A, Giugliano D, D'Onofrio F, and Howard BV. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes. Diabetologia 41: 1127-1132, 1998.
24. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, and Ravussin E. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 38: 1213-1217, 1995.
25. Piatti PM, Monti LD, Davis SN, Conti M, Brown MD, Pozza G, and Alberti KG. Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM patients. Diabetologia 39: 103-112, 1996.
26. Qvigstad E, Bjerve KS, and Grill V. Effects of long term fasting on insulin responses to fatty acids in man. Scand J Clin Lab Invest 62: 271-278, 2002.
27. Randle PJ. Regulatory interactions between lipids and carbohydrates: The glucose fatty acid cycle after 35 years. Diabetes Metab Rev 14: 263-283, 1998.
28. Randle PJ, Kerbey AL, and Espinal J. Mechanisms decreasing glucose oxidation in diabetes and starvation: Role of lipid fuels and hormones. Diabetes Metab Rev 4: 623-638, 1988.
29. Rimestad AH, Blaker B, Flåten A-M, and Nordbotten A. Den Store Matvaretabellen [The Norwegian Food Table]. Oslo, Norway: Universitetsforlaget, 1995.
30. Sako Y and Grill VE. A 48-h lipid infusion in the rat timedependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 127: 1580-1589, 1990.
31. Saloranta C, Groop L, Ekstrand A, Franssila-Kallunki A, Eriksson J, and Taskinen MR. Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes. Diabet Med 10: 950-957, 1993.
32. Shih KC, Kwok CF, Hwu CM, Hsiao LC, Li SH, Liu YF, and Ho LT. Acipimox attenuates hypertriglyceridemia in dyslipidemic noninsulin dependent diabetes mellitus patients without perturbation of insulin sensitivity and glycemic control. Diabetes Res Clin Pract 36: 113-119, 1997.
33. Stefan N, Fritsche A, Haring H, and Stumvoll M. Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptorgamma2 gene. Diabetes 50: 1143-1148, 2001.
34. UK Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes: A progressive disease. UK Prospective Diabetes Study 16. Diabetes 44: 1249-1258, 1995.
35. Warnotte C, Gilon P, Nenquin M, and Henquin JC. Mechanisms of the stimulation of insulin release by saturated fatty acids. A study of palmitate effects in mouse beta-cells. Diabetes 43: 703-711, 1994.
36. Wiesenthal SR, Sandhu H, McCall RH, Tchipashvili V, Yoshii H, Polonsky K, Shi ZQ, Lewis GF, Mari A, and Giacca A. Free fatty acids impair hepatic insulin extraction in vivo. Diabetes 48: 766-774, 1999.
37. Wolfe RR. Metabolic interactions between glucose and fatty acids in humans. Am J Clin Nutr 67: 519S-526S, 1998.
38. Zambon A, Hashimoto SI, and Brunzell JD. Analysis of techniques to obtain plasma for measurement of levels of free fatty acids. J Lipid Res 34: 1021-1028, 1993.
39. Zhou YP, Berggren PO, and Grill V. A fatty acid-induced decrease in pyruvate dehydrogenase activity is an important determinant of beta-cell dysfunction in the obese diabetic db/db mouse. Diabetes 45: 580-586, 1996.
40. Zhou YP and Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 93: 870-876, 1994.
41. Zhou YP and Grill V. Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab 80: 1584-1590, 1995.
42. Zhou YP and Grill VE. Palmitate-induced beta-cell insensitivity to glucose is coupled to decreased pyruvate dehydrogenase activity and enhanced kinase activity in rat pancreatic islets. Diabetes 44: 394-399, 1995.